Indian Hypertension Battle: New Study Crowns Telmisartan-Amlodipine for Better BP Control

A recently published study, the START RENAL 2026, reveals that a fixed-dose combination (FDC) of telmisartan-amlodipine significantly outperforms telmisartan-cilnidipine in lowering blood pressure (BP) for Indian patients battling hypertension and renal impairment. The critical findings, detailed in the April 2026 issue of the International Journal of Nephrology and Renovascular Disease, indicate that while both combinations offered comparable benefits for kidney health, telmisartan-amlodipine delivered a superior reduction in systolic blood pressure (SBP). This breakthrough comes as India grapples with a massive hypertension epidemic, affecting over 220 million people with alarmingly low control rates, especially in rural areas. Fixed-dose combination are a game-changer for improving patient adherence and achieving better BP control, but choosing the right one is key. The study, an open-label, randomized trial conducted across six Indian centers, highlights that telmisartan-amlodipine greater SBP reduction, even for high-risk diabetic patients, provides a crucial advantage in managing this widespread health crisis. For doctors across India, this update from the START RENAL 2026 study could signal a shift in treatment preferences for patients with both high blood pressure and kidney issues. The clearer efficacy of telmisartan-amlodipine in lowering SBP, coupled with its similar kidney-protective profile, offers a more defined path for prescribing. As pharmaceutical companies respond to these findings, we can expect tailored treatment strategies to emerge, potentially leading to better health outcomes for millions of Indians facing chronic conditions.